PAULINE STOLTZNER: Open Payments
NPI 1205376589 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$949 in 53 payments from 17 companies in 2025. Trend: 2023 $1,879 · 2024 $1,224 · 2025 $949
Food & beverage: $949
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $237 |
| AstraZeneca Pharmaceuticals LP | 8 | $150 |
| PFIZER INC. | 6 | $103 |
| Amgen Inc. | 4 | $88 |
| MAYNE PHARMA COMMERCIAL LLC | 6 | $59 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Tris Pharma Inc | 1 | $24 |
Products named: QULIPTA, OTEZLA, VRAYLAR, BREZTRI, NURTEC ODT, AUSTEDO XR, CAPLYTA, FANAPT.
Industry payments across NV — which companies pay providers there.
